Cargando…

Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases

The possibility of using interleukin 2 (IL-2)-activated natural killer cells (A-NK) to carry methoxymorpholinyl doxorubicin (MMDX; PNU 152243) to liver-infiltrating tumours was explored in mice bearing 2-day established M5076 reticulum cell sarcoma hepatic metastases. In vitro, MMDX was 5.5-fold mor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quintieri, L, Rosato, A, Amboldi, N, Vizler, C, Ballinari, D, Zanovello, P, Collavo, D
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362260/ https://www.ncbi.nlm.nih.gov/pubmed/10098738 http://dx.doi.org/10.1038/sj.bjc.6690171

Ejemplares similares

Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity.
por: Vizler, C., et al.
Publicado: (1998)

Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker.
por: Lau, D. H., et al.
Publicado: (1994)

L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.
por: Geroni, C., et al.
Publicado: (1994)

In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
por: Ripamonti, M., et al.
Publicado: (1992)

Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats
por: Carbó, N, et al.
Publicado: (2000)

Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK(1) receptors
por: Palma, C, et al.
Publicado: (1999)

Temporary inhibition of Moloney-murine sarcoma virus (M-MSV) induced-tumours by adoptive transfer of ricin-treated T-lymphocytes.
por: Cerundolo, V., et al.
Publicado: (1987)

Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002)

Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants
por: Pavillard, V, et al.
Publicado: (2001)

Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
por: Platel, D, et al.
Publicado: (1999)

Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function
por: Muzzammil, T, et al.
Publicado: (2001)

Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients withelanoma
por: Boyano, M D, et al.
Publicado: (2000)

Targeted delivery of doxorubicin by nano-loaded mesenchymal stem cells for lung melanoma metastases therapy
por: Zhao, Yuekui, et al.
Publicado: (2017)

Time-dependent simvastatin administration enhances doxorubicin toxicity in neuroblastoma
por: Anderson, Colin C., et al.
Publicado: (2020)

Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice
por: Balsari, A, et al.
Publicado: (2001)

Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion
por: Kanai, T, et al.
Publicado: (2000)

Protein binding of 4-hydroxybenzoic acid and 4-hydroxy-3-methoxybenzoic acid to human serum albumin and their anti-proliferation on doxorubicin-sensitive and doxorubicin-resistant leukemia cells
por: Myint, Ohnmar, et al.
Publicado: (2021)

The effect of adjuvant cyclophosphamide or tamoxifen on the numbers of lymphocytes bearing T cell or NK cell markers.
por: Sheard, C. R., et al.
Publicado: (1986)

Caspase-3 activation during apoptosis caused by glutathione–doxorubicin conjugate
por: Asakura, T, et al.
Publicado: (1999)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Nanoporous 3D-Printed Scaffolds for Local Doxorubicin Delivery in Bone Metastases Secondary to Prostate Cancer
por: Ahangar, Pouyan, et al.
Publicado: (2018)

Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance
por: Zhao, Yuan, et al.
Publicado: (2016)

Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2001)

Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma
por: Fontanini, G, et al.
Publicado: (1999)

Increased doxorubicin uptake and toxicity in multicellular tumour spheroids treated with DC electrical fields
por: Sauer, H, et al.
Publicado: (1999)

Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females
por: Zanetta, G, et al.
Publicado: (1999)

Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)
por: Gaillard, Pieter J., et al.
Publicado: (2014)

Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562
por: Sargent, J M, et al.
Publicado: (2001)

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
por: Koukourakis, M I, et al.
Publicado: (2000)

Doxorubicin and Trifolium pratense L. (Red clover) extract synergistically inhibits brain and lung metastases in 4T1 tumor‐bearing BALB/c mice
por: Akbaribazm, Mohsen, et al.
Publicado: (2020)

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma
por: Johansson, M, et al.
Publicado: (2000)

Markers of bone turnover for the management of patients with bone metastases from prostate cancer
por: Garnero, P, et al.
Publicado: (2000)

Induction of Fos protein expression in spinal cord neurons of tumour-bearing rats
por: Kergozien, S, et al.
Publicado: (1999)

A polymorphism of the interleukin-1 β gene influences survival in pancreatic cancer
por: Barber, M D, et al.
Publicado: (2000)

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine
por: Nocera, M, et al.
Publicado: (2000)

Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases
por: Jayne, D G, et al.
Publicado: (2000)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
por: Fokkema, E, et al.
Publicado: (2000)

In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6
por: Speirs, V, et al.
Publicado: (1999)

Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma
por: Matsumoto*, T, et al.
Publicado: (1999)

Day–night pattern of energy expenditure and body temperature in cachectic tumour-bearing rats
por: Oudart, H, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_q5p2sph6oe2rrs9r885i9m52uc